基于网络药理学的瓜蒌薤白桂枝汤治疗冠心病作用机制研究。
Study on the mechanism of Gualou Xiebai Guizhi decoction (GLXBGZD) in the treatment of coronary heart disease based on network pharmacology.
机构信息
Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, Shandong, China.
Shandong Public Health Clinical Center, Jinan, Shandong, China.
出版信息
Medicine (Baltimore). 2022 Jul 22;101(29):e29490. doi: 10.1097/MD.0000000000029490.
BACKGROUND
This study aims to analyze the mechanism of Gualou Xiebai Guizhi decoction (GLXBGZD) in treating coronary heart disease (CHD) utilizing network pharmacology.
METHODS
The GLXBGZD effective components were searched on the pharmacological database platform of the Traditional Chinese Medicine Systems Pharmacol, and its potential target was predicted. The Online Mendelian Inheritance obtained CHD disease target in Man and GeneCards database. The Venn map of the intersection target for GLXBGZD and CHD was constructed by using Venn online website. The "drug-component-target-disease" network map was constructed by Cytoscape 3.7.2 software. The DAVID online platform was used to analyze the function of Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) at the intersection of targets of drugs and diseases.
RESULTS
A total of 27 articles were searched for GLXBGZD, including 111 potential targets, 5521 disease targets, 100 drug and disease intersection targets. The core target network map shows that Interleukin (IL)-6, TNF, vascular endothelial growth factor (VEGFA), TP53, EGF, JUN, MAPK1, Catalase (CAT), and prostaglandin-endoperoxide synthase 2 (PTGS2) may be the key targets in CHD therapy. GO functional enrichment analysis revealed that the biological functions of GLXBGZD involved biological processes such as response to drugs, positive regulation of nitric oxide biosynthesis process, and response to hypoxia. KEGG pathway enrichment analysis showed that GLXBGZD might participate in CHD treatment through Hypoxia-inducible factor-1 (HIF-1), Tumor necrosis factor (TNF), PhosphoInositide-3 Kinase--Threonine protein kinase (PI3K-Akt), and the calcium signal pathway.
CONCLUSIONS
This study reveals that the GLXBGZD mechanism in CHD treatment has the characteristics of multi-components, multi-targets, and multi-pathways, which provides a theoretical basis for its clinical application and subsequent experimental verification.
背景
本研究旨在利用网络药理学分析瓜蒌薤白桂枝汤（GLXBGZD）治疗冠心病（CHD）的作用机制。
方法
在中药系统药理学药理学数据库平台上搜索 GLXBGZD 的有效成分，并预测其潜在靶点。从在线 Mendelian 遗传数据库（OMIM）和基因数据库（GeneCards）获得 CHD 疾病靶点。通过 Venn 在线网站构建 GLXBGZD 与 CHD 的交集靶点的 Venn 图。使用 Cytoscape 3.7.2 软件构建“药物-成分-靶点-疾病”网络图。通过 DAVID 在线平台对药物与疾病靶点交集的基因本体论（GO）富集和京都基因与基因组百科全书（KEGG）进行分析。
结果
共检索到 GLXBGZD 相关文献 27 篇，包括 111 个潜在靶点、5521 个疾病靶点、100 个药物与疾病交集靶点。核心靶点网络图显示，白细胞介素（IL）-6、肿瘤坏死因子（TNF）、血管内皮生长因子（VEGFA）、TP53、表皮生长因子（EGF）、JUN、丝裂原活化蛋白激酶 1（MAPK1）、过氧化氢酶（CAT）和前列腺素内过氧化物合酶 2（PTGS2）可能是 CHD 治疗的关键靶点。GO 功能富集分析显示，GLXBGZD 的生物学功能涉及药物反应、一氧化氮生物合成过程的正调控和缺氧反应等生物学过程。KEGG 通路富集分析表明，GLXBGZD 可能通过缺氧诱导因子-1（HIF-1）、肿瘤坏死因子（TNF）、磷酸肌醇 3 激酶-苏氨酸蛋白激酶（PI3K-Akt）和钙信号通路参与 CHD 的治疗。
结论
本研究揭示了 GLXBGZD 治疗 CHD 的作用机制具有多成分、多靶点、多途径的特点，为其临床应用及后续实验验证提供了理论依据。
Zotero 插件